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Copyright © 200? JCBN Summary Metabolome analyses assisted by capillary electrophoresis-mass spectrometry
(CE-MS) have allowed us to systematically grasp changes in small molecular metabolites
under disease conditions. We applied CE-MS to mine out biomarkers in hepatic ischemia-
reperfusion. Rat livers were exposed to ischemia by clamping of the portal inlet followed by
reperfusion. Metabolomic profiling revealed that l contents of taurine in liver and plasma were
significantly increased. Of interest is an elevation of hypotaurine, collectively suggesting
significance of hypotaurine/taurine in post-ischemic responses. Considering the anti-oxidative
capacity of hypotaurine, we examined if supplementation of the compound or its precursor
amino acids could affect hepatocellular viability and contents of taurine in liver and plasma.
Administration of hypotaurine, N-acetylcysteine or methionine upon reperfusion comparablly
attenuated the post-ischemic hepatocellular injury but with different metabolomic profiling
among groups: rats treated with methionine or N-acetylcysteine but not those treated with
hypotaurine, exhibited significant elevation of hepatic lactate generation without notable
recovery of the energy charge. Furthermore, the group treated with hypotaurine exhibited
elevation of the plasma taurine, suggesting that the exogenously administered compound was
utilized as an antioxidant. These results suggest that taurine serves as a surrogate marker for
ischemia-reperfusion indicating effectiveness of hypotaurine as an energy-saving hepato-
protective amino acid.
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Introduction
Ischemia-reperfusion injury has been proposed to result
from a burst of reactive oxygen species (ROS) generated
upon reperfusion, and administration of antioxidants at the
onset of reperfusion diminished the post-ischemic injury [1].
There are multiple resources of ROS upon reperfusion;
endothelial cells, leukocytes and mitochondria mainly in
parenchymal cells that constitute major cellular fraction for
O2 consumption [2, 3]. In case of the reperfusion injury of
the liver, site-specific delivery of superoxide dismutase
(SOD) to endothelial cells serves as a potentially effective
strategy to attenuate the injury [4]. On the other hand, only
limited methods have been available to attenuate ROS from
the mitochondrial origin. In other words, there is a paucity of
availability of small molecular anti-oxidative compounds
that can directly access the site of ROS generation in hepato-
cytes.Taurine as a Biomarker Mined by Metabolome
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In this context, application of N-acetylcysteine (NAC)
might serve as one of the important compounds widely used
to attenuate such an intracellular resource of ROS [5]. This
compound is believed to enter the cells and catalyzed to
produce cysteine as a precursor of reduced glutathione
(GSH) or as a direct antioxidant by itself [5, 6]. However,
little evidence has been provided for evidence whether
administration of NAC might alter metabolic systems as a
whole to promote other beneficial effects besides scavenging
ROS or any unidentified harmful effects on the reperfused
liver.
To solve this question, we aimed to investigate alterations
in small molecular metabolites in ischemia-reperfused rat
liver, and to examine effects of administration of NAC on
major metabolic pathways. To this end, we have utilized
metabolome analyses based on capillary electrophoresis
equipped with mass spectrometry (CE-MS) for systematic
mining of biomarkers indicating the reperfusion injury of
the liver [7–9]. The current results suggest that the post-
ischemic liver exhibits remarkable increases in hepatic
contents of hypotaurine and taurine after reperfusion, which
coincided with a notable elevation of taurine in circulation.
Furthermore, administration of NAC enrich two important
antioxidant systems including both GSH and hypotaurine,
while increasing hepatic lactate contents. To be noted is
that a comparable dose of hypotaurine itself effectively
attenuate the reperfusion injury independently of GSH
enrichment, suggesting its crucial role against hepatic
ischemia-reperfusion injury.
Materials and Methods
Animals and surgical operation for ischemia/reperfusion
model
The experimental protocols herein described were
approved by our institutional guidelines provided by the
Animal Care Committee of Keio University School of
Medicine. Male Wistar rats weighting 220 to 280 g were
used. The rats were allowed free access to laboratory chow
and tap water, and were fasted for 18 h prior to experiments.
They were anesthetized with an intraperitoneal injection of
sodium pentobarbital at 50 mg/kg. The abdomen was
opened by midline incision. To avoid effects of splanchnic
blood congestion, we used the model of partial liver ischemia
[10]. The ischemia was induced by selective clamping of
branches of the portal vein and hepatic artery supplying
the left lateral and left median liver lobes. After 1 h of the
ischemia, the vascular clamp was released to establish
reperfusion for 1, 3 or 6 h. After the removal of vascular
clamp, the abdomen was closed in two layers. In sham
operation, the abdomen was opened and the liver was
manipulated similarly except for clamping of portal vein and
hepatic artery.
After warm ischemia/reperfusion or sham operation, liver
tissues were collected by snap frozen procedures [11].
Briefly, the portal vein was cannulated with a 16-gauge
catheter, into which Krebs-Henseleit bicarbonate buffer
cooled at 4°C was infused to remove blood. The aorta and
inferior vena cava were dissected as the outflow tract. Liver
samples were immediately frozen with liquid nitrogen and
stored at −40°C for later analysis. Five main protocols were
employed in groups treated with 1-h ischemia followed by
desired lengths of time for reperfusion: Livers in the first
group were treated with an intraperitoneal injection of
physiological saline as a vehicle at the start of reperfusion.
In the second to the fifth groups, methionine (Met), NAC,
hypotaurine (HTU) and taurine (TU) dissolved in physio-
logical saline were intraperitoneally administered at the
start of reperfusion at desired doses, respectively. The doses
used in the current study were 1.5 mmol/kg [12–15]. These
experiments were conducted to examine if hypotaurine and
its precursor amino acids such as methionine or cysteine
could improve post-ischemic injury of the liver through the
antioxidative property of the compound.
Metabolome analysis
We performed metabolome analyses of tissue lysates
collected from snap-frozen livers of rat using CE-MS
according to our previous methods [7]. At desired periods of
time for reperfusion, the abdominal incision was reopened
for excising livers to be snap-frozen by liquid nitrogen and
minced in cold methanol. In this study, we carried out
determination of metabolites at 1, 3 and 6 h after the start of
reperfusion, and compared effects of the aforementioned
amino acids on the reperfusion injury at 3 h. The lysates
served as samples for CE-MS analyses as reported pre-
viously [7, 8]. In separate sets of experiments, liver samples
collected from the groups were minced with 10% trichloro-
acetic acid at 4°C to measure cysteine and GSH through
HPLC to confirm the data collected from CE-MS.
Statistical analyses
All data in this study were expressed as mean ± SD.
Differences in the mean values among the groups were
analyzed by one-way ANOVA combined with Fisher’s-type
multiple comparison test. p values smaller than 0.05 were
considered statistically significant.
Results
Metabolomic profiling of hepatic ischemia-reperfusion
Table 1 indicated temporal alterations in metabolomic
profiling of hepatic contents of metabolites. The data were
normalized by the baseline values measured in the non-
ischemic control group, and expressed as fold changes as a
function of time until 6 h after reperfusion. Among metabo-T. Sakuragawa et al.
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lites indicating up-regulating responses after reperfusion,
taurine and hypotaurine were those showing remarkable
elevation by 2–3 folds versus the baseline. On the other
hand, those decreased significantly at 1 h after reperfusion
were ATP and GTP; these metabolites were recovered
partially during the later time points of measurements. On
the other hand, other metabolites that were not listed in
Table 1 did not exhibit any significant changes during the
course of observations.
Exogenous methionine or N-acetylcysteine attenuates post-
ischemic liver injury
Fig. 1 illustrates the magnitudes of hepatocellular injury
induced by 3-h reperfusion following ischemia which were
judged by the leakage of ALT and GLDH into circulation
and indicates the effects of post-ischemic administration of
Met, NAC, HTU or TU. As shown, post-treatment of one of
these reagents but not of TU significantly attenuated the
release of the enzymes, indicating protective actions of
these reagents against oxidative tissue injury by ischemia-
reperfusion.
Since results of metabolome analysis suggested notable
changes in metabolism of hypotaurine and taurine, we next
examined effects of Met, NAC or HTU on hepatic contents
of taurine and its plasma concentration. Figure 2 illustrates
results at 3 h after reperfusion in each group. As seen, the
tissue contents of taurine increased by 2 folds versus the
control level, and the treatment with Met, NAC or HTU did
not greatly alter the taurine contents. On the other hand, the
plasma concentration of taurine turned out to increase by 2.5
Table 1. Alterations in hepatic contents of metabolites after the post-ischemic reperfusion periods
Note that metabolomic profiling of the metabolites post of ischemia-reperfusion as described in Materials and Methods.
The data were expressed as those normalized by the average values of non-ischemic controls. Values are mean ± SE of
4 separate experiments. *p<0.05 as compared with the control values.
Contents of metabolites 
(vs non-ischemic control)
I/R 1 h I/R 3 h I/R 6 h
Increased metabolites
Taurine 1.81 ± 0.18* 2.61 ± 0.22* 2.90 ± 0.34*
Hypotaurine 1.08 ± 0.30 2.35 ± 0.73 3.71 ± 1.53*
Citrate 1.28 ± 0.17 1.74 ± 0.22* 0.99 ± 0.23
CMP 1.18 ± 0.14 1.55 ± 0.14* 1.67 ± 0.23*
Adenosine 1.37 ± 0.22 1.54 ± 0.20 1.48 ± 0.39
Glutamate 1.36 ± 0.27 1.46 ± 0.17 0.95 ± 0.11
S-Adenosyl-L-homocysteine 1.14 ± 0.13 1.45 ± 0.14 1.33 ± 0.32
CDP 0.94 ± 0.12 1.40 ± 0.19* 1.60 ± 0.06*
S-Adenosyl-L-methionine 0.89 ± 0.12 1.24 ± 0.25 1.00 ± 0.22
CTP 0.68 ± 0.13 1.14 ± 0.14 1.27 ± 0.05
AMP 1.16 ± 0.13 1.02 ± 0.02 1.06 ± 0.08
NAD 0.84 ± 0.04* 1.00 ± 0.04 1.04 ± 0.06
Decreased metabolites
ADP 0.92 ± 0.12 0.97 ± 0.06 1.05 ± 0.04
GMP 1.13 ± 0.08 0.96 ± 0.04 0.96 ± 0.15
NADH 0.95 ± 0.09 0.94 ± 0.06 0.88 ± 0.07
Glutathione 0.67 ± 0.09 0.93 ± 0.08 0.62 ± 0.08*
GDP 0.92 ± 0.10 0.90 ± 0.03 0.89 ± 0.04
ATP 0.65 ± 0.10* 0.81 ± 0.09 0.92 ± 0.04
Glycine 1.05 ± 0.12 0.78 ± 0.08 0.80 ± 0.15
GTP 0.66 ± 0.10* 0.76 ± 0.07* 0.77 ± 0.08
Methionine 0.85 ± 0.08 0.74 ± 0.19 0.72 ± 0.04
FAD 0.86 ± 0.02 0.70 ± 0.05* 0.75 ± 0.03*
NADPH 0.86 ± 0.14 0.69 ± 0.04* 0.65 ± 0.08*
CoA 0.64 ± 0.08 0.68 ± 0.07 0.67 ± 0.24
NADP 0.79 ± 0.03* 0.66 ± 0.03* 0.69 ± 0.05*
Acetyl CoA 0.65 ± 0.23 0.23 ± 0.05* 0.62 ± 0.17Taurine as a Biomarker Mined by Metabolome
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folds in response to reperfusion, suggesting that taurine
might serve as a surrogate marker indicating the hepatic
reperfusion injury that is detectable in circulation.
To be noted is that administration of NAC or HTU in the
model significantly increased plasma taurine concentration.
Considering the results indicating that the NAC or HTU
treatment did not increase the hepatic taurine contents, these
results raised a possibility that administration of NAC or
HTU might be metabolized in vivo to serve as a resource
of de novo taurine synthesis to be excreted from the liver
into circulation. To examine this hypothesis, we compared
differences in metabolomic profiles among the experimental
groups. Fig. 3 indicated a portion of results collected from
CE-MS-based metabolome analyses that focused on sulfur-
containing amino acid metabolism. As seen, the group
treated with Met indicated a remarkable elevation of Met,
S-adenosylmethionine (SAM), and S-adenosylhomocysteine
(SAH) in remethylation cycle as well as cystathionine
located at transsulfuration pathway. Other important changes
were increases in hypotaurine and reduced form of GSH,
suggesting that exogenous Met is utilized for enrichment of
the anti-oxidative substrates in the post-ischemic liver.
Observation that supplementation of Met from the top of
remethylation and transsulfuration pathways increased the
Fig. 1. Hepatoprotective effects of sulfur-containing amino acids such as methionine (Met), N-acetylcysteine (NAC), hypotaurine
(HTU) and taurine (TU) on hepatocellular injury caused by 3-h reperfusion following 1-h ischemia in the rat liver. Control and
I/R indicate the sham-operated control group and that treated with ischemia-reperfusion, respectively. The aminoacids were
administered immediately after the onset of reperfusion. Data indicate those measured at 3 h after reperfusion and were
expressed as mean ± SE of 5–15 separate experiments. *p<0.05 vs the I/R group. †p<0.05 vs the data in the I/R group treated
with vehicles.
Fig. 2. Effects of methionine (Met), N-acetylcysteine (NAC) or hypotaurine (HTU) on hepatic contents and plasma concentrations of
taurine. Data measured at 3 h after reperfusion were shown. Data were expressed as mean ± SE of 5–8 separate experiments.
*p<0.05 as compared with the control group. †p<0.05 vs the data in the I/R group.T. Sakuragawa et al.
J. Clin. Biochem. Nutr.
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downstream antioxidants such as GSH and hypotaurine led
us to speculate that exogenous administered NAC might also
be converted to the two different antioxidants. As expected,
the supplementation of NAC significantly increased both
GSH and hypotaurine, but without altering contents of the
upstream metabolites such as Met, SAM, SAH and
cystathionine. Under the given dose, both Met and NAC
resulted in comparable supplementation of GSH and HTU,
being in good agreement with the results showing both
supplements comparably attenuated the hepatocellular injury
(Fig. 1).
HTU attenuates the injury without enhancing the GSH
system
The current results showing the comparability of hepato-
protective effects between Met and NAC and their beneficial
effects on increased contents of GSH and hypotaurine led
us to inquire which antioxidant system might play a crucial
role against hepatocellular injury caused by ischemia-
reperfusion of the liver. To answer to the inquiry, effects of
the comparable dose of HTU were examined using the same
protocol. As seen in Fig. 3, The HTU-treated liver exhibited
significant elevation of the hepatic contents of HTU and
accordingly, the ratio between HTU and TU. Taken together
with the observation in Fig. 2 that the same treatment
significantly increased plasma taurine concentration, these
results suggest that exogenously administered HTU converted
to TU to serve as an antioxidant to protect against the cell
injury. Another important feature of the exogenous HTU
administration that was not seen in the Met or NAC treat-
ment was the absence of GSH elevation: In the HTU-treated
liver, oxidized form of glutathione (GSSG) was significantly
elevated versus other groups. This observation was consis-
tent with a notion that, in the HTU-treated group, endo-
genous GSH is consumed as a result of oxidative stress
without being supplied by the upstream substrates.
HTU but not Met nor NAC improves energy charge in the
post-ischemic liver injury
Results of metabolome analysis displayed a distinct effect
Fig. 3. Altertaions in metabolites gelongingto remethylation and transsulfuration pathways upon administration of sulfur-containing
amino acids such as methionine (Met), N-acetylcysteine (NAC) and hypotaurine (HTU). SAM: S-adenosylmethionine, SAH:
S-adenosylhomocysteine. Note that the protective effects of hypotaurine which was shown in Fig. 1 occur independently of
GSH supplementation. Values are mean ± SE of 5–8 separate experiments. *p<0.05 vs the control. †p<0.05 vs the I/R-treated
group. #p<0.05 vs the I/R + Met group.Taurine as a Biomarker Mined by Metabolome
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of HTU from that of Met or NAC in a profile of nucleotide
contents in the post-ischemic liver. Figure 4 illustrates the
tissue contents of ATP, ADP and AMP and energy charges
calculated from these data collected at 3 h after the start of
reperfusion. As seen, treatment with Met or NAC did not
improve contents of ATP, while increasing contents of ADP
and AMP. As a result, the value of energy charge was not
improved in these groups. On the other hand, The HTU
treatment significantly attenuated tissue contents of ADP
and AMP, while not altering the ATP contents in the post-
ischemic liver, and resulted in a significant recovery of the
energy charge value.
Treatment with Met or NAC but not with HTU aggravates
lactate overproduction in the post-ischemic liver
Exogenously administered amino acids have been known
to undergo transamination and oxidative deamination to
produce carbohydrates that serve as substrates for tricar-
bonic acid (TCA) cycle and gluconeogenesis in the liver.
Since the effects on energy charge were different between
Met- or NAC- and HTU-treated post-ischemic livers, we
compared the response of carbohydrate metabolism in-
cluding glycolysis, gluconeogenesis and TCA cycle. As seen
in Fig. 5, the group treated with 3-h reperfusion following
the ischemia displayed a significant decrease in acetyl CoA
and increases in citrate, succinate, malate and phospho-
enolpyruvate (PEP). In the groups treated with Met, the
decrease in acetyl CoA was significantly recovered, while
that with NAC displayed a marked elevation of Acetyl CoA,
presumably because of supplementation with the acetyl
group from the compound. In the groups treated with Met or
NAC, hepatic contents of lactate and fructose 6-phosphate
were significantly elevated. On the other hand, the group
treated with HTU did neither exhibit any remarkable
changes in TCA substrates nor induce the elevation of
lactate and fructose 6-phopsphate. These results suggest
that HTU did neither trigger gluconeogenesis nor accelerate
glycolysis in the post-ischemic liver tissue.
Discussion
The current study using CE-MS-based metabolome anal-
Fig. 4. Hepatic contents of ATP, ADP and AMP and energy charges measured at 3 h after the start of reperfusion. Note that the HTU-
treated group significantly attenuated tissue contents of ADP and AMP, without lowering ATP in the post-ischemic liver,
leading to a significant recovery of the energy charge. Values are mean ± SE of 5–8 separate experiments. *p<0.05 vs the
control. †p<0.05 vs the I/R-treated group.T. Sakuragawa et al.
J. Clin. Biochem. Nutr.
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Fig. 5. Altertaions in carbohydrate metabolism in glycolysis/gluconeogenesis and TCA cycle upon administration of methionine (Met),
N-acetylcysteine (NAC) and hypotaurine (HTU) in the ischemia-reperfused rat liver. Note that the group treated with Met or
NAC, but not that with HTU, exhibited significant elevation of lactate. Values are mean ± SE of 5–8 separate experiments.
*p<0.05 vs the control. †p<0.05 vs the I/R-treated group. #p<0.05 vs the I/R + Met group.Taurine as a Biomarker Mined by Metabolome
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ysis first provided evidence that taurine serves as a surrogate
marker indicating warm ischemia-reperfusion injury of the
liver. Furthermore, the study revealed that administration of
hypotaurine, the precursor of taurine, significantly attenuated
the post-ischemic liver injury without aggravating energy
metabolism and lactate overproduction. On the other hand,
either NAC, a precursor of cysteine widely used for an anti-
oxidant accessible to the intracellular space, or Met turned
out to aggravate the energy charge values through incorpo-
rating into TCA cycle to be utilized as a substrate for gluco-
neogenesis, while these compounds exert their hepato-
protective ability against the post-ischemic insults. It is
unknown why hypotaurine serves as an energy-saving anti-
oxidant as compared with NAC. However, so far as judged
from the data indicating effects of NAC on alterations in
amounts of TCA substrates and gluconeogenesis, it is not
unreasonable to speculate that, through being catalized into
cysteine and acetate, the compound might provide acetyl
CoA for the substrate and increases gluconeogenic substrates
such as PEP and fructose 6-phosphate. Since gluconeo-
genesis is an energy-consuming process, such a hypothesis
is in good agreement with the metabolome data that indicate
accumulation of gluconeogenic products and decreased
energy charge.
The present study also revealed that distinct role between
GSH/GSSG and hypotaurine/taurine systems for anti-
oxidative defense mechanisms in the liver. In the groups
treated with Met or NAC, the post-ischemic liver increased
contents of GSH through providing cysteine as the pre-
cursor. The ratio between GSH versus GSSG was well
conserved in both Met-treated and NAC-treated groups. On
the other hand the post-ischemic liver treated with hypo-
taurine, the GSH/GSSG ratio was significantly reduced
presumably because of elevated oxidation of GSH into
GSSH through a paucity of de novo supply of GSH during
post-ischemic oxidative stress. Under these circumstances,
however, exogenously administered hypotaurine appeared
to be converted into taurine to exert its anti-oxidative
property aginst the injury. Distinct from the GSH/GSSH
system, hypotaurine seems to be a suicide antioxidative
compound that is oxidized by ROS [16–18] to form taurine
that is excreted through its transporter into the extracellular
space. Because of such nature of the compound, the results
of the present study suggest that effects of extracellularly
administered hypotaurine could be estimated by monitoring
the increase in plasma concentrations of taurine as seen in
Fig. 2.
In the present study, metabolome analysis allowed us to
reveal diverse effects of NAC. This compound has widely
been used as a potent antioxidant both experimentally and
clinically [6], and its major effect has been thought to be an
increase in the GSH/GSSG ratio. So far as seen in the
present results, once administered in vivo, NAC increases
both GSH and hypotaurine to potentiate the ROS-scavenging
capacity. In addition to such effects, the compound appeared
to undergo deamination to produce pyruvate that accounts
for substrate of varied carbohydrate products including
lactate, TCA cycle products and PEP. In other words, an
excess overload of gluconeogenic substrates upon exo-
genous administration of amino acids might jeopardize the
energy state of the liver through energy-consuming gluco-
neogenesis. In this context, the current results suggest that
hypotaurine serves as an energy-saving antioxidant protecting
against post-ischemic oxidative injury.
Acknowledgments
This work was supported by Leading Project for Bio-
simulation and by Next Generation Supercomputing Sciences
and Applications from RIKEN.
Abbreviations
ALD, aldolase; ALT, alanine transferase; CE-MS, capillary
electrophoresis-mass spectrometry; ENO, enolase; F1,6BP,
fructose 1,6-bisphosphate; F6P, fructose 6-phosphate;
GAPDH, glyceraldehydephosphate dehydrogenase; GLDH,
glutamate dehydrogenase; GSH, glutathione; GSSG, oxidized
form of glutathione; G1P, glucose 1-phosphate; G6P, glucose
6-phosphate; HTU, hypotaurine; LDH, lactate dehydroge-
nase; Met, methionine; NAC, N-acetylcysteine; PEP,
phosphoenolpyruvate; PFK, phosphofructokinase; 3PG, 3-
phosphoglycerate; PGI, phosphoglucoisomerase; PGK,
phosphoglycerate kinase; PGM, phosphoglycerate mutase;
PK, pyruvate kinase; ROS, reactive oxygen species; SAH,
S-adenosylhomocysteine; SAM, S-adenosylmethionine;
SOD, superoxide dismutase; TU, taurine.
References
[1] Rosseland, C.M., Wierod, L., Oksvold, M.P., Werner, H.,
Ostvold, A.C., Thoresen, G.H., Paulsen, R.E., Huitfeldt, H.S.,
and Skarpen, E.: Cytoplasmic retention of peroxide-activated
ERK provides survival in primary cultures of rat hepatocytes.
Hepatology, 42, 200–207, 2005.
[2] Suzuki, H., Suematsu, M., Ishii, H., Kato, S., Miki, H., Mori,
M., Ishimura, Y., Nishino, T., and Tsuchiya, M.: Pro-
staglandin E1 abrogates early reductive stress and zone-
specific paradoxical oxidative injury in hypoperfused rat
liver. J. Clin. Invest., 93, 155–164, 1994.
[3] Jaeschke, H.: Molecular mechanisms of hepatic ischemia-
reperfusion injury and preconditioning. Am. J. Physiol.
Gastrointest. Liver Physiol., 284, G15–26, 2003.
[4] Nakazono, K., Watanabe, N., Matsuno, K., Sasaki, J., Sato,
T., and Inoue, M.: Does superoxide underlie the pathogenesis
of hypertension? Proc. Natl. Acad. Sci. U.S.A., 88, 10045–
10048, 1991.T. Sakuragawa et al.
J. Clin. Biochem. Nutr.
134
[5] Zafarullah, M., Li, W.Q., Sylvester, J., and Ahmad, M.:
Molecular mechanisms of N-acetylcysteine actions. Cell Mol.
Life Sci., 60, 6–20, 2003.
[6] Yan, M., Qiang, W., Liu, N., Shen, J., Lynn, W.S., and Wong,
P.K.: The ataxia-telangiectasia gene product may modulate
DNA turnover and control cell fate by regulating cellular
redox in lymphocytes. Faseb J., 15, 1132–1138, 2001.
[7] Soga, T., Baran, R., Suematsu, M., Ueno, Y., Ikeda, S.,
Sakurakawa, T., Kakazu, Y., Ishikawa, T., Robert, M.,
Nishioka, T., and Tomita, M.: Differential metabolomics
reveals ophthalmic acid as an oxidative stress biomarker
indicating hepatic glutathione consumption. J. Biol. Chem.,
281, 16768–16776, 2006.
[8] Kinoshita, A., Tsukada, K., Soga, T., Hishiki, T., Ueno, Y.,
Nakayama, Y., Tomita, M., and Suematsu, M.: Roles of
hemoglobin allostery in hypoxia-induced metabolic altera-
tions in erythrocytes: simulation and its verification by
metabolome analysis. J. Biol. Chem.,  282, 10731–10741,
2007.
[9] Shintani, T., Iwabuchi, T., Soga, T., Kato, Y., Yamamoto, T.,
Takano, N., Hishiki, T., Ueno, Y., Ikeda, S., Sakuragawa, T.,
Ishikawa, K., Goda, N., Kitagawa, Y., Kajimura, M.,
Matsumoto, K., and Suematsu, M.: Cystathionine β-synthase
as a carbon monoxide-sensitive regulator of bile excretion.
Hepatology, 49, 141–150, 2009.
[10] Schauer, R.J., Gerbes, A.L., Vonier, D., op den Winkel, M.,
Fraunberger, P., and Bilzer, M.: Induction of cellular
resistance against Kupffer cell-derived oxidant stress: a novel
concept of hepatoprotection by ischemic preconditioning.
Hepatology, 37, 286–295, 2003.
[11] Tejima, K., Arai, M., Ikeda, H., Tomiya, T., Yanase, M.,
Inoue, Y., Nagashima, K., Nishikawa, T., Watanabe, N.,
Omata, M., and Fujiwara, K.: Ischemic preconditioning
protects hepatocytes via reactive oxygen species derived
from Kupffer cells in rats. Gastroenterology,  127, 1488–
1496, 2004.
[12] Koeppel, T.A., Lehmann, T.G., Thies, J.C., Gehrcke, R.,
Gebhard, M.M., Herfarth, C., Otto, G., and Post, S.: Impact
of N-acetylcysteine on the hepatic microcirculation after
orthotopic liver transplantation. Transplantation, 61, 1397–
1402, 1996.
[13] Dunne, J.B., Piratvisuth, T., Williams, R., and Tredger, J.M.:
Treatment of experimental ischemia/reperfusion injury with
S-adenyosylmethionine: evidence that donor pretreatment
complements other regimens. Transplantation, 63, 500–506,
1997.
[14] Nakano, H., Nagasaki, H., Barama, A., Boudjema, K., Jaeck,
D., Kumada, K., Tatsuno, M., Baek, Y., Kitamura, N.,
Suzuki, T., and Yamaguchi, M.: The effects of N-
acetylcysteine and anti-intercellular adhesion molecule-1
monoclonal antibody against ischemia-reperfusion injury of
the rat steatotic liver produced by a choline-methionine-
deficient diet. Hepatology, 26, 670–678, 1997.
[15] Jeon, B.R. and Lee, S.M.: S-adenosylmethionine protects
post-ischemic mitochondrial injury in rat liver. J. Hepatol.,
34, 395–401, 2001.
[16] Aruoma, O.I., Halliwell, B., Hoey, B.M., and Butler, J.: The
antioxidant action of taurine, hypotaurine and their metabolic
precursors. Biochem. J., 256, 251–255, 1988.
[17] Pecci, L., Montefoschi, G., Fontana, M., Dupre, S., Costa,
M., and Cavallini, D.: Hypotaurine and superoxide dismutase:
protection of the enzyme against inactivation by hydrogen
peroxide and peroxidation to taurine. Adv. Exp. Med. Biol.,
483, 163–168, 2000.
[18] Fontana, M., Giovannitti, F., and Pecci, L.: The protective
effect of hypotaurine and cysteine sulphinic acid on per-
oxynitrite-mediated oxidative reactions. Free Radic. Res., 42,
320–330, 2008.